SelankvsVilon

Selank is a synthetic heptapeptide based on the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with a stabilizing Pro-Gly-Pro extension at the C-terminus that dramatically increases its resistance to aminopeptidase degradation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it was designed to combine the immune-enhancing effects of tuftsin with anxiolytic and nootropic properties.

The anxiolytic mechanism involves modulation of GABAergic neurotransmission. Selank acts as an allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA in anxiety-related brain regions including the amygdala, hippocampus, and prefrontal cortex. This produces a benzodiazepine-like anxiolytic effect without the sedation, cognitive impairment, or addiction potential associated with benzodiazepines — because Selank modulates rather than directly activates the receptor. Additionally, Selank stabilizes enkephalins (endogenous opioid pentapeptides) by inhibiting enkephalin-degrading enzymes (aminopeptidases and enkephalinase/neprilysin), prolonging their mood-regulating and anxiolytic signaling.

The nootropic effects are mediated through neurotrophic factor upregulation. Selank increases expression of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex, promoting dendritic branching, synaptic plasticity, and long-term potentiation — the cellular mechanisms underlying memory formation and cognitive flexibility. It also modulates serotonergic (5-HT) metabolism, altering the balance between serotonin and its metabolite 5-HIAA in key brain regions. The immunomodulatory component derives from the tuftsin core: tuftsin naturally activates monocytes and macrophages through specific receptors, enhancing phagocytic activity and modulating IL-6, TNF-α, and other cytokine production. This immune regulation occurs at sub-anxiolytic doses, suggesting it is an independent pharmacological effect. The combined anxiolytic, cognitive-enhancing, and immunomodulatory profile is unique among available peptides.

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator developed as part of the Khavinson peptide bioregulator program, designed to mimic the immune-regulatory effects of thymic peptides in the shortest possible amino acid sequence. As a dipeptide, it is one of the smallest molecules proposed to have specific gene-regulatory activity — which is both its appeal (simplicity, stability, oral bioavailability) and the source of scientific skepticism (whether a two-amino-acid molecule can have specific transcriptional effects).

Vilon is proposed to regulate thymic function and T-cell immunity through the peptide bioregulator mechanism: penetrating cell membranes, entering the nucleus, and interacting with specific DNA sequences in immune-related gene promoters. The reported effects include enhanced T-cell differentiation from thymic precursors, improved balance between CD4+ helper and CD8+ cytotoxic T cell populations, and modulation of cytokine production toward a more balanced Th1/Th2 immune profile.

Preclinical and clinical studies from the Khavinson group have reported that Vilon treatment enhances immune surveillance (the ability of the immune system to detect and eliminate abnormal cells), improves vaccine responsiveness in elderly subjects, and partially reverses age-related immunosenescence markers. In combination with Epithalon (another Khavinson bioregulator targeting telomerase and the pineal gland), Vilon was reported to reduce mortality in a long-term follow-up study of elderly subjects in St. Petersburg. The proposed mechanism for immune enhancement involves restoration of thymic peptide signaling that declines with age-related thymic involution, essentially providing a minimal molecular signal that tells immune progenitor cells to differentiate and mature. As with all Khavinson bioregulators, independent validation through Western clinical trial standards is still needed.